International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 067-070
CLADRIBINE TREATMENT OUTCOMES OF HAIRY CELL LEUKEMIA

Abdullah ALTINTAŞ1, Orhan AYYILDIZ1, Ahmet E. ATAY2, Timuçin ÇİL2, Ekrem MÜFTÜOĞLU1

1Dicle Üniversitesi Tıp Fakültesi Hematoloji-Onkoloji Anabilim Dalı
2Dicle Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı

Keywords: Hairy cell leukemia, Cladribine
Hairy cell leukemia is a rare, clonal, chronic B cell lenfoproliferative disease characterized by splenomegaly and pancytopenia. Purine analogues are first-line choice of therapy. Although effectivity of treatment is established, relapses may occur. In this state, remission may achieved by a new cycle of 2-CdA or alternative modalities. In this report, we represented the results of our patients with HCL that were treated with 2-CdA and followed up in our center.